PF-05089771
![]() | |
Legal status | |
---|---|
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C18H12Cl2FN5O3S2 |
Molar mass | 500.34 g·mol−1 |
3D model (JSmol) | |
| |
|
PF-05089771 is a selective, small-molecule Nav1.7 and Nav1.8 voltage-gated sodium channel blocker under development by Pfizer as a novel analgesic.[1][2][3] As of June 2014, it has completed phase II clinical trials for wisdom tooth removal and primary erythromelalgia.[4]
See also
[edit]References
[edit]- ^ McMahon SB, Koltzenburg M, Tracey I, Turk D (March 2013). Wall & Melzack's Textbook of Pain. Elsevier Health Sciences. p. 508. ISBN 978-0702053740.
- ^ Martz L (June 2014). "Nav-i-gating antibodies for pain". SciBX: Science-Business EXchange. 7 (23): 662. doi:10.1038/scibx.2014.662.
- ^ Alexandrou AJ, Brown AR, Chapman ML, Estacion M, Turner J, Mis MA, et al. (6 April 2016). "Subtype-Selective Small Molecule Inhibitors Reveal a Fundamental Role for Nav1.7 in Nociceptor Electrogenesis, Axonal Conduction and Presynaptic Release". PLOS ONE. 11 (4): e0152405. Bibcode:2016PLoSO..1152405A. doi:10.1371/journal.pone.0152405. PMC 4822888. PMID 27050761.
- ^ Bagal SK, Chapman ML, Marron BE, Prime R, Storer RI, Swain NA (August 2014). "Recent progress in sodium channel modulators for pain". Bioorganic & Medicinal Chemistry Letters. 24 (16): 3690–3699. doi:10.1016/j.bmcl.2014.06.038. PMID 25060923.
External links
[edit]- "PF-05089771". AdisInsight. Springer Nature Switzerland AG.